How DrugVoice’s Message Resonance Score™ helps Pharma and Agencies understand whether launch messaging is connecting with HCPs.
Launch is a recurring theme in Pharma conversations right now, from early-stage planning to post-launch optimization. But while launch strategies are carefully developed, timelines agreed, and campaigns delivered, one important question remains: how well are Healthcare Professionals (HCPs) actually resonating with the messages behind a brand?
For Pharma and Agencies, understanding this distinction is essential. Delivering a consistent scientific narrative is one thing. Knowing whether that narrative is reflected in HCP conversations is another.
DrugVoice addresses this challenge through its Message Resonance Score™, helping Strategy and Client teams understand how intended messages are reflected in real-world healthcare conversations.
Because launch success is not just about what a brand says. It is also about what HCPs say next.
Launch planning is only part of the picture
Pharmaceutical launches involve significant investment in strategy, scientific communication, and HCP engagement. Strategy and Client teams work to establish clear positioning, communicate clinical evidence, and build understanding among the audiences who matter.
Yet HCP perception does not remain static throughout a launch. It evolves as new evidence emerges, congress presentations generate discussion, Key Opinion Leaders (KOLs) share their perspectives, and clinicians exchange views with peers.
These conversations can reveal where brand messages are resonating, where interpretations differ, and which competing narratives are influencing the wider discussion.
Traditional campaign measures can help Pharma and Agencies understand reach and engagement. However, they do not necessarily explain whether HCPs are aligning with the intended scientific narrative, which messages are resonating most strongly, or how that resonance changes over time.
Without this understanding, Strategy and Client teams risk relying on what they intended to communicate rather than what the market is actually telling them.
Measuring what resonates with HCPs
HCP resonance goes beyond message awareness. It is about understanding how Healthcare Professionals interpret, discuss, and respond to the ideas underpinning a brand’s positioning. Are HCPs engaging with the intended clinical benefits? Which aspects of the evidence are generating the most discussion? Are competitor narratives shaping perceptions? And are the priorities expressed in HCP conversations consistent with the messages a brand is trying to establish?
DrugVoice’s Message Resonance Score™ provides a way to assess how brand messaging is reflected in HCP conversations, helping Pharma and Agencies move beyond message delivery to understand how their scientific narratives are being received.
This intelligence can inform decision-making at every stage of the launch journey.
Before launch, it can help establish an understanding of the existing conversation and the narratives shaping the therapy area. At launch, it can help Pharma and Agencies assess how intended messages are resonating as HCP discussion develops. After launch, ongoing analysis can reveal how perceptions evolve and which topics continue to influence the conversation.
By making message resonance measurable, DrugVoice helps Strategy and Client teams develop a more informed view of launch performance and identify where further investigation or communication may be needed.
What GLP-1 conversations reveal about launch intelligence
GLP-1 therapies in obesity and weight management provide a useful case study in why understanding HCP resonance matters.
As the conversation around these therapies evolves, understanding their place in clinical practice requires more than tracking discussion of short-term weight loss. Longer-term health outcomes, adherence, persistence, and the overall Patient experience also form part of the picture.
In our DrugVoice launch intelligence use case, we examined HCP conversations around GLP-1 therapies to understand how scientific narratives were being interpreted in practice.
One of the strongest signals to emerge was the value HCPs placed on long-term health outcomes, adherence, persistence, and the overall Patient experience, rather than focusing solely on short-term weight loss claims.
The analysis also highlighted the influence of competitor narratives and key KOL voices on HCP interpretation.
These findings illustrate why launch intelligence needs to extend beyond the delivery of brand messaging. Understanding what is shaping HCP perspectives can help Pharma and Agencies assess whether their intended narratives are gaining traction, identify areas where perceptions may differ, and recognize the wider conversations influencing their market.
Through the Message Resonance Score™, DrugVoice offers a way to bring this focus on message alignment into launch intelligence, helping Strategy and Client teams understand how intended messaging relates to the conversations taking place around a therapy area.
The opportunity is not simply to measure whether a message has been delivered, but to understand how it resonates.
Explore the DrugVoice Launch Excellence use case in obesity and weight management.
From messaging consistency to measurable resonance
For Pharma and Agencies, this represents an important evolution in launch excellence. Consistent messaging remains essential. But consistency alone cannot demonstrate whether HCPs interpret that messaging as intended or how their perspectives change throughout a product’s lifecycle.
DrugVoice transforms unstructured healthcare conversations into structured, actionable intelligence, helping Pharma and Agencies explore message resonance, understand audience perspectives, and monitor how conversations evolve over time. The Message Resonance Score™ supports a more focused approach to understanding how brand narratives are reflected in HCP discussion. This can help Strategy and Client teams:
- Establish a pre-launch baseline. Understand existing HCP perspectives and the narratives already shaping the therapy area before introducing a new brand message.
- Assess resonance during launch. Explore how HCP conversations reflect intended messaging and identify areas where interpretations may differ.
- Understand competing narratives. Examine how competitor messaging, KOL commentary, and wider clinical discussions influence the conversation.
- Monitor changes over time. Continue to assess HCP resonance after launch, rather than treating launch day as the end point of measurement.
- Inform communications strategy. Use evidence from real-world conversations to help refine scientific narratives and make engagement strategies more responsive to HCP perspectives.
Together, these applications help Pharma and Agencies move from measuring communication activity to developing a clearer picture of how messages are being received.
Launch excellence does not end at launch
A successful launch is not a single moment. It is a journey in which scientific evidence, clinical perspectives, and market conversations continue to interact.Understanding HCP resonance throughout that journey helps Pharma and Agencies move beyond measuring activity toward developing a clearer picture of how messages connect, where perceptions differ, and what may need attention next.DrugVoice’s Message Resonance Score™ brings this focus into launch intelligence, helping Strategy and Client teams understand how their intended messages are reflected in HCP conversations before launch, at launch, and throughout the product lifecycle.
For Pharma and Agencies investing in launch excellence, the question is no longer only whether the right message reached the right audience. It is whether that message is being understood, discussed, and reflected in the conversations shaping clinical practice.Because the more Pharma and Agencies understand what HCPs are saying, the better informed they can be about what to communicate next.
Continue the conversation
Whether you are preparing for an upcoming launch, assessing campaign performance, or looking to strengthen HCP alignment across a product’s lifecycle, DrugVoice can help you explore the intelligence within real-world healthcare conversations.
Discover how DrugVoice’s Message Resonance Score™ can help you understand HCP resonance and strengthen launch intelligence.
Explore our GLP-1 Launch Excellence use case or get in touch with the DrugVoice team to continue the conversation.